

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the trea...
Q1 2027
Aug 13, 2026
FY 2026
May 14, 2026
Q4 2026
May 14, 2026
Q3 2026
Mar 25, 2026
Q2 2026
Dec 31, 2025